BWS Financial Raises PT on Life Science Research (LSR) to $38
More News related to LSR
- Life Sciences Research (LSR) Reports Q2 Earnings
- BWS Financial Raises PT on Life Science Research (LSR) to $38
- BWS Financial Starts Life Sciences Research (LSR) at Buy
- LSRI Said the NYSE Approves Listing
More News related to Analyst Comments
- Buckingham Research Maintains a 'Neutral' Rating on Wal-Mart (WMT), See Upside/Downside Fairly Balanced
- Wedbush Morgan Maintains a 'Hold' on Majesco Holdings (COOL), Impressed With Progress But Investors Remain Skeptical
- Wedbush Morgan Maintains a 'Hold' on Family Dollar Stores (FDO), Raises Price Target and Estimates
- Wedbush Morgan Maintains a 'Buy' on ON Semiconductor (ONNN), Raises Price Target
- Analyst Round-Up: Intuitive Surgical (ISRG) - 3 Downgrades, 2 Price Target Cuts
BWS Financial raises its price target on Life Science Research (NYSE: LSR) from $28 to $38. The firm has a Buy rating on the stock.
The firm believes that Life Science Research's solid Q1 earnings suggested that pharmaceutical companies are continuing to move towards contract research organizations and away from in-house research operations. BWS notes that LSR stock trades at a discount to its two largest competitors, but believes this will not remain "for too long given increases in the operating margin."
Going forward, BWS expects LSR to continue trending higher due to more new business and sequential improvements in operating margins.
Life Sciences Research, Inc. operates as a contract research organization worldwide. [BCS]
Related Categories
Analyst CommentsStocks Mentioned
-0.29Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
